Telix Pharmaceuticals Limited (ASX:TLX)

Telix Pharmaceuticals Revenue

Telix Pharmaceuticals had revenue of $477.35M USD in the half year ending June 30, 2026, with 99.22% growth. This brings the company's total for the last twelve months to $890.79M, up 167.52% year-over-year. In the year 2025, Telix Pharmaceuticals had annual revenue of $803.79M with 55.61% growth. That makes Telix Pharmaceuticals the 8,058th largest company in the world by revenue and 138th in Australia.

• Revenue (ttm): $890.79M
• Revenue Growth: +167.52%
• P/S Ratio: 3.38
• Revenue / Employee: $752.35K
• Employees: 1,184
• Market Cap: 4.35B AUD

Revenue Chart

Chart

Chart

* This company reports financials in USD.

Revenue by Segment

By Segment

Chart

• Precision Medicine 621.93M 71.0%
• Manufacturing Solutions 245.11M 28.0%
• Therapeutics 9.27M 1.1%

By Geography

Chart

• United States 784.91M 97.7%
• China 9.83M 1.2%
• Other Countries 9.06M 1.1%

Fiscal year ended Dec 31, 2025 See the full Telix Pharmaceuticals breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	803.79M	287.24M	55.61%
Dec 31, 2024	516.55M	183.57M	55.13%
Dec 31, 2023	332.98M	224.03M	205.64%
Dec 31, 2022	108.95M	103.42M	1,873.24%
Dec 31, 2021	5.52M	1.51M	37.53%
Dec 31, 2020	4.01M	1.57M	64.21%
Dec 31, 2019	2.44M	2.31M	1,680.88%
Dec 31, 2018	137.28K	-	-
Dec 31, 2017	-	-	-

Data Sources: Fiscal.ai and S&P Global Market Intelligence Last updated: Jun 30, 2026

Revenue data is provided by Fiscal.ai and updates within minutes after each earnings release, which is every six months for this company. Revenue segment and geography data is provided by S&P Global Market Intelligence.

Update frequency:

Semi-annually

Last checked:

Oct 27, 2026

Data Sources Report a data error